A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Description of Business. The Company operates Polomar Specialty Pharmacy, LLC, a State of Florida licensed retail compounding pharmacy, located in Palm Harbor, FL, pursuant to license # PH35196. Polomar Specialty Pharmacy is also licensed as a Special Sterile Compounding Pharmacy, permit #PH35277, which authorizes the licensed entity to dispense injectable and other sterile compounds (eye drops, infused therapeutics) upon receipt of a valid prescription. The compounding facility operates pursuant to guidelines established under Sec. 503A “Compounding Pharmacy” of the Federal Food, Drug and Cosmetic Act. Section 503A authorizes the licensed entity to manufacture compounded drugs and fulfill prescriptions provided to it by licensed physicians. As a result, the Company is presently authorized to fulfill and deliver compounded prescribed medications in 28 states.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 37K | - | 0 | 0 |
| Net Income | -2.4M | -1.3M | -588K | -181K |
| EPS | $-0.09 | $-0.05 | $-0.02 | $-0.00 |
| Free Cash Flow | 0 | -1.1M | -534K | -41K |
| ROIC | -20.9% | -15.6% | -325.2% | -97.0% |
| Gross Margin | 55.1% | - | 0.0% | 0.0% |
| Debt/Equity | 0.13 | 0.13 | -3.40 | 0.37 |
| Dividends/Share | $0.00 | - | $0.00 | $0.00 |
| Operating Income | -2.3M | -1.3M | -441K | -181K |
| Operating Margin | -6199.8% | - | 0.0% | 0.0% |
| ROE | -31.3% | -31.4% | - | -97.0% |
| Shares Outstanding | 28M | 27M | 29M | 11M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | 0 | N/A | 37K |
| Gross Margin | 0.0% | 0.0% | N/A | 55.1% |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | 216K | 450K | 1.3M | 2.3M |
| EBIT | -181K | -441K | -1.3M | -2.3M |
| Op. Margin | 0.0% | 0.0% | N/A | -6199.8% |
| Net Income | -181K | -588K | -1.3M | -2.4M |
| Net Margin | 0.0% | 0.0% | N/A | -6562.4% |
| Non-Recurring | 0 | 0 | 65K | 0 |
| Returns on Capital | ||||
| ROIC | -97.0% | N/M | -15.6% | -20.9% |
| ROE | -97.0% | N/A | -31.4% | -31.3% |
| ROA | -69.3% | -549.0% | -26.7% | -26.2% |
| Cash Flow | ||||
| Op. Cash Flow | -41K | -534K | -1.0M | -901K |
| Free Cash Flow | -41K | -534K | -1.1M | 0 |
| Owner Earnings | -215K | -714K | -1.3M | -1.9M |
| CapEx | 0 | 0 | 91K | 0 |
| Maint. CapEx | 0 | 6K | 263K | 1.0M |
| Growth CapEx | N/A | N/A | 0 | 0 |
| D&A | 0 | 6K | 263K | 1.0M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | N/A | 0.0% |
| Stock-Based Comp | 174K | 174K | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -382K | N/A | 1.1M | 917K |
| Cash & Equiv. | 226K | 9K | 6K | 78K |
| Long-Term Debt | N/A | N/A | N/A | 994K |
| Debt/Equity | 0.37 | -3.40 | 0.13 | 0.13 |
| Interest Coverage | -1314.9 | -890.6 | -31.1 | -31.1 |
| Equity | 187K | -45K | 8.6M | 7.8M |
| Total Assets | 261K | 107K | 10.0M | 9.3M |
| Total Liabilities | 75K | 152K | 1.4M | 1.5M |
| Intangibles | N/A | N/A | 250K | 250K |
| Retained Earnings | -982K | -1.6M | -2.9M | -4.6M |
| Working Capital | 187K | -90K | -1.3M | -1.3M |
| Current Assets | 261K | 12K | 77K | 198K |
| Current Liabilities | 75K | 102K | 1.3M | 1.5M |
| Per Share Data | ||||
| EPS | -0.00 | -0.02 | -0.05 | -0.09 |
| Owner EPS | -0.02 | -0.02 | -0.05 | -0.07 |
| Book Value | 0.02 | -0.00 | 0.32 | 0.28 |
| Cash Flow/Share | -0.00 | -0.02 | -0.04 | -0.05 |
| Dividends/Share | 0.00 | 0.00 | N/A | 0.00 |
| Shares Out. | 10.9M | 29.4M | 26.8M | 28.1M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -1.8 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 0.7 | 0.6 |
| Price/Sales | N/A | N/A | N/A | 121.2 |
| FCF Yield | N/A | N/A | -17.6% | N/A |
| Market Cap | 0 | 0 | 6.3M | 4.5M |
| Avg. Price | 0.00 | 0.00 | 1.42 | 0.16 |
| Year-End Price | 0.00 | 0.00 | 0.24 | 0.16 |
Polomar Health Services, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Polomar Health Services, Inc. (PMHS) has a 5-year average return on invested capital (ROIC) of -56.3%. This is below average and may indicate limited pricing power.
Polomar Health Services, Inc. (PMHS) has a market capitalization of $4M. It is classified as a small-cap stock.
Polomar Health Services, Inc. (PMHS) does not currently pay a regular dividend.
Polomar Health Services, Inc. (PMHS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Polomar Health Services, Inc. (PMHS) generated $-1 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Polomar Health Services, Inc. (PMHS) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
Polomar Health Services, Inc. (PMHS) reported earnings per share (EPS) of $-0.05 in its most recent fiscal year.
Polomar Health Services, Inc. (PMHS) has a return on equity (ROE) of -31.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Polomar Health Services, Inc. (PMHS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Polomar Health Services, Inc. (PMHS) has a book value per share of $0.32, based on its most recent annual SEC filing.
No recent press releases.